Medical devices, healthcare technology and the business of care
PMA SUPPLEMENT · P040045/S147

VISTAKON (senofilcon A) Brand Contact Lenses

Vistakon, Division of Johnson & Johnson Vision Car · Decision date Oct 16, 2026

MEDTECHLEDGER EXPLANATIONP040045/S147

What did the FDA decide?

The FDA record P040045/S147, decided October 16, 2026 under decision code OK30, is a 30-Day Notice filed for Vistakon (senofilcon A) Brand Contact Lenses in the soft extended-wear lens category (product code LPM, Ophthalmic). The stated change is the addition of an alternate raw material supplier for the color additive used in the manufacturing process for lens visible handling, at facilities in Jacksonville, Florida and Limerick, Ireland. The supplement number ties the filing to PMA P040045 as a supplement, not as an original approval of the device system.

The notice is classified as a process change covering manufacturer, sterilizer, packager or supplier. The source statement gives the supplier addition as the reported purpose; it does not present independent proof of safety or clinical effectiveness, and none should be read into the decision code. Absent from the supplied fields are the identity of the added supplier, the specifications of the color additive, and the validation data supporting the change.

FDA approval order statement

addition of alternate raw material supplier for the color additive used in the manufacturing process for Vistakon (senofilcon A) Brand Contact Lenses for lens visible handling, at the manufacturing facilities located in Jacksonville, Florida and Limerick, Ireland
Regulatory pathway
PMA supplement
Supplement type
30-Day Notice
Clinical specialty
Ophthalmic
Decision date
Oct 16, 2026
FDA change category
Process Change - Manufacturer/Sterilizer/Packager/Supplier

FDA source record · MedtechLedger’s explanation describes the recorded change.

Regulatory record facts

Identifier
P040045/S147
Regulatory pathway
PMA supplement
Product code
LPM
Decision code
OK30
Decision date
Oct 16, 2026
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: Lenses, soft contact, extended wear.

Product code
LPM
FDA device class
3

For the original device and its historical approval scope, see PMA P040045. Subsequent supplements may change the device or its indications.

FDA decision timeline

  1. P040045 · Original PMA

    VISTAKON (SENOFILCON A) CONTACT LENS, CLEAR AND VISIBILITY TINTED WITH UV BLOCKER

  2. P040045/S145 · Related supplement

    VISTAKON (SENOFILCON A) CONTACT LENS, CLEAR AND VISIBILITY TINTED WITH UV BLOCKER

  3. P040045/S147 received

    Application receipt date recorded by FDA.

  4. P040045/S146 · Related supplement

    VISTAKON (SENOFILCON A) Brand Contact Lenses

  5. P040045/S147 · FDA decision

    30-Day Notice

Timeline entries are records held by MedtechLedger for P040045. View FDA’s full supplement list.

Related devices and submissions

Same PMA: P040045

Explore the linked device profile

Other records with product code LPM

Product / regulatory recordCompanyPathwayDecision dateSource
Bausch and Lomb, Inc.,PMA supplementSep 14, 2026FDA
CooperVision, Inc.PMA supplementSep 2, 2026FDA
Bausch and Lomb, Inc.,PMA approvalApr 30, 2018FDA
CooperVision, Inc.PMA approvalNov 19, 2008FDA

A shared product code identifies a classification relationship; it does not establish clinical equivalence.

Regulatory context

A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

Vistakon, Division of Johnson & Johnson Vision Car

Headquarters
Not reported
Brand website
Not reported
FDA applicant address
7500 Centurion Pkwy., Suite 100 - Erca, Jacksonville, FL, 32256

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records